Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04035486
Recruitment Status : Recruiting
First Posted : July 29, 2019
Last Update Posted : October 14, 2021
Sponsor:
Information provided by (Responsible Party):
AstraZeneca